دورية أكاديمية
EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome.
العنوان: | EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome. |
---|---|
المؤلفون: | da Costa BHB; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil., Becker AP; The Ohio State University, Department of Radiation Oncology, Columbus, OH, USA., Neder L; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; Department of Pathology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil., Gonçalves PG; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; UNESP - Univ. Estadual Paulista, School of Medicine, Department of Pathology, Botucatu, São Paulo, Brazil., de Oliveira C; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; UNESP - Univ. Estadual Paulista, School of Medicine, Department of Pathology, Botucatu, São Paulo, Brazil., Polverini AD; Department of Neurosurgery, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Clara CA; Department of Neurosurgery, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Teixeira GR; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil.; Department of Pathology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil., Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal., Bidinotto LT; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil.; UNESP - Univ. Estadual Paulista, School of Medicine, Department of Pathology, Botucatu, São Paulo, Brazil. |
المصدر: | Journal of pathology and translational medicine [J Pathol Transl Med] 2022 Jul; Vol. 56 (4), pp. 205-211. Date of Electronic Publication: 2022 Jun 15. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Korean Society of Pathologists/Korean Society of Cytopathology Country of Publication: Korea (South) NLM ID: 101650151 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2383-7837 (Print) Linking ISSN: 23837837 NLM ISO Abbreviation: J Pathol Transl Med Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Seoul : Korean Society of Pathologists/Korean Society of Cytopathology, [2015]- |
مستخلص: | Background: Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal growth factor-like domain multiple 7 (EGFL7) expression and unfavorable outcome of pilocytic astrocytoma patients. The present study aims to analyze the prognostic potential of EGFL7 in GBM isocitrate dehydrogenase (IDH)-wildtype, using immunohistochemistry and in silico approaches. Methods: Spearman's correlation analysis of The Cancer Genome Atlas RNA sequencing data was performed. The genes strongly correlated to EGFL7 expression were submitted to enrichment gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Additionally, EGFL7 expression was associated with patient overall survival. The expression of EGFL7 was analyzed through immunohistochemistry in 74 GBM IDH-wildtype patients' samples, and was associated with clinicopathological data and overall survival. Results: In silico analysis found 78 genes strongly correlated to EGFL7 expression. These genes were enriched in 40 biological processes and eight KEGG pathways, including angiogenesis/vasculogenesis, cell adhesion, and phosphoinositide 3-kinase-Akt, Notch, and Rap1 signaling pathways. The immunostaining showed high EGFL7 expression in 39 cases (52.7%). High immunolabelling was significantly associated with low Karnofsky Performance Status and poor overall survival. Cox analysis showed that GBMs IDH-wildtype with high EGFL7 expression presented a higher risk of death compared to low expression (hazard ratio, 1.645; 95% confidence interval, 1.021 to 2.650; p = .041). Conclusions: This study gives insights regarding the genes that are correlated with EGFL7, as well as biological processes and signaling pathways, which should be further investigated in order to elucidate their role in glioblastoma biology. |
References: | J Cancer Res Ther. 2018;14(4):867-872. (PMID: 29970668) Oncologist. 2004;9(2):197-206. (PMID: 15047924) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Dev Dyn. 2004 Jun;230(2):316-24. (PMID: 15162510) Neoplasma. 2019 Mar 5;66(2):187-196. (PMID: 30569717) Curr Biol. 2006 Sep 19;16(18):1796-806. (PMID: 16979556) J Clin Oncol. 2010 Jun 20;28(18):3061-8. (PMID: 20479398) Nucleic Acids Res. 2009 Jan;37(1):1-13. (PMID: 19033363) J Gynecol Oncol. 2014 Oct;25(4):334-41. (PMID: 25142627) G3 (Bethesda). 2016 Jul 07;6(7):1867-78. (PMID: 27172220) Cancer Lett. 2017 Jan 1;384:9-18. (PMID: 27725228) Clin Cancer Res. 2020 Feb 1;26(3):669-678. (PMID: 31672772) Oncologist. 2017 Apr;22(4):375-e30. (PMID: 28275117) Int J Biol Markers. 2013 Apr 23;28(1):71-83. (PMID: 23558933) Stem Cell Reports. 2019 Jun 11;12(6):1250-1259. (PMID: 31155507) Blood. 2010 Dec 23;116(26):6133-43. (PMID: 20947685) Bioinformatics. 2016 Mar 15;32(6):952-4. (PMID: 26568634) J Biol Chem. 2014 Jun 20;289(25):17689-98. (PMID: 24790104) Trends Mol Med. 2009 Nov;15(11):519-30. (PMID: 19889578) Oncologist. 2018 Jun;23(6):654-e58. (PMID: 29438092) Methods Mol Biol. 2009;472:323-42. (PMID: 19107440) Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4641-E4647. (PMID: 28533390) Neuropathology. 2021 Feb;41(1):21-28. (PMID: 33191640) Cancer Biol Ther. 2019;20(10):1314-1318. (PMID: 31306053) J Cancer Res Clin Oncol. 2010 Nov;136(11):1737-43. (PMID: 20213100) Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877) Curr Pharm Des. 2020;26(15):1729-1741. (PMID: 32003685) J Cell Biochem. 2018 Dec;119(12):10327-10337. (PMID: 30129142) Cell Cycle. 2010 Apr 1;9(7):1263-9. (PMID: 20372059) Nat Rev Mol Cell Biol. 2001 May;2(5):369-77. (PMID: 11331911) Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076) Nature. 2004 Apr 15;428(6984):754-8. (PMID: 15085134) Sci Rep. 2017 May 24;7(1):2388. (PMID: 28539619) Novartis Found Symp. 2007;283:18-28; discussion 28-36, 238-41. (PMID: 18300411) Sci China Life Sci. 2018 Aug;61(8):893-901. (PMID: 29951953) N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009) Biomed Pharmacother. 2016 Feb;77:167-75. (PMID: 26796281) |
معلومات مُعتمدة: | 2018/20737-1 The São Paulo Research Foundation; 2017/09749-5 The São Paulo Research Foundation; 2016/21727-4 The São Paulo Research Foundation; 472447/2013-0 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior |
فهرسة مساهمة: | Keywords: EGFL7; Glioblastoma IDH-wildtype; Notch pathway; PI3K-Akt pathway; Rap1 pathway |
تواريخ الأحداث: | Date Created: 20220614 Latest Revision: 20220731 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC9288890 |
DOI: | 10.4132/jptm.2022.04.22 |
PMID: | 35698739 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!